Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan, Shandong Province 250012, People's Republic of China.
ACS Appl Mater Interfaces. 2020 Aug 26;12(34):38499-38511. doi: 10.1021/acsami.0c06872. Epub 2020 Aug 13.
The tumor penetration of nanomedicines constitutes a great challenge in the treatment of solid tumors, leading to the highly compromised therapeutic efficacy of nanomedicines. Here, we developed small morph nanoparticles (PDMA) by modifying polyamidoamine (PAMAM) dendrimers with dimethylmaleic anhydride (DMA). PDMA achieved deep tumor penetration via an active, energy-dependent, caveolae-mediated transcytosis, which circumvented the obstacles in the process of deep penetration. PDMA remained negatively charged under normal physiological conditions and underwent rapid charge reversal from negative to positive under acidic conditions in the tumor microenvironment (pH < 6.5), which enhanced their uptake by tumor cells and their deep penetration into tumor tissues and . The deep tumor penetration of PDMA was achieved mainly by caveolae-mediated transcytosis, which could be attributed to the small sizes (5-10 nm) and positive charge of the morphed PDMA. studies demonstrated that PDMA exhibited increased tumor accumulation and doxorubicin-loaded PDMA (PDMA/DOX) showed better antitumor efficacy. Overall, the small morph PDMA for enhanced deep tumor penetration via caveolae-mediated transcytosis could provide new inspiration for the design of anticancer drug delivery systems.
纳米药物的肿瘤穿透性是实体瘤治疗中的一大挑战,导致纳米药物的治疗效果大大降低。在这里,我们通过用马来酸二甲酯(DMA)修饰聚酰胺-胺(PAMAM)树状大分子来开发小形态纳米粒子(PDMA)。PDMA 通过主动的、能量依赖的、小窝蛋白介导的胞吞作用实现了深层肿瘤穿透,从而避开了深层穿透过程中的障碍。在正常生理条件下,PDMA 保持负电荷,而在肿瘤微环境(pH < 6.5)下的酸性条件下,迅速从负电荷转变为正电荷,这增强了肿瘤细胞对其的摄取和向肿瘤组织的深层渗透。PDMA 的深层肿瘤穿透主要通过小窝蛋白介导的胞吞作用实现,这归因于其较小的尺寸(5-10nm)和正电荷。体内研究表明,PDMA 表现出增加的肿瘤积累,载多柔比星的 PDMA(PDMA/DOX)显示出更好的抗肿瘤功效。总的来说,通过小窝蛋白介导的胞吞作用增强深层肿瘤穿透的小形态 PDMA 为设计抗癌药物输送系统提供了新的启示。
ACS Appl Mater Interfaces. 2020-8-26
Eur J Pharm Biopharm. 2018-2-27
Nanomaterials (Basel). 2025-8-3
Acta Pharm Sin B. 2025-2
Front Bioeng Biotechnol. 2023-9-12
Nanomaterials (Basel). 2022-12-24
Biomimetics (Basel). 2022-11-30
J Nanobiotechnology. 2022-6-25